ArticleCureus2026
Herpes Zoster Following Chemo-Immunotherapy With Pembrolizumab in Metastatic Non-small Cell Lung Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChemo-immunotherapy has reshaped the treatment of metastatic non-small cell lung cancer (NSCLC), yet data on varicella-zoster virus (VZV) reactivation under these regimens are limited. Major immunotherapy trials do not specifically describe herpes zoster events in patients receiving combined chemotherapy and immune checkpoint inhibitors.
methodsWe describe a case of metastatic lung adenocarcinoma (ADC) treated with first‑line Pemetrexed-Carboplatin-Pembrolizumab plus Denosumab in which herpes zoster occurred during treatment, detailing clinical course, management, and outcomes.
resultsWe report a 64-year-old former smoker with metastatic lung ADC involving lymph nodes and bone, Programmed Cell Death Protein Ligand (PD-L1) expression 0%, and no actionable oncogenic alterations. He was treated with first-line Pemetrexed-Carboplatin-Pembrolizumab plus Denosumab. Treatment was well tolerated, and post-cycle 4 imaging showed stable disease according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. Approximately four months after initiation of chemo-immunotherapy, he developed a painful, unilateral, dermatomal vesicular eruption over the right lower thorax, clinically consistent with herpes zoster. The diagnosis of herpes zoster was clinical rather than microbiological. Systemic anticancer therapy was temporarily suspended. The patient received oral Acyclovir, step II analgesics, and local wound care for 14 days. Complete resolution of skin lesions and pain occurred within three weeks, without zoster-related complications. Maintenance Pemetrexed-Pembrolizumab-Denosumab was then resumed, with sustained tumor control and no recurrence of herpes zoster during follow-up.
conclusionThis case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.